Ubs Group Ag Glycomimetics Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Glycomimetics Inc stock. As of the latest transaction made, Ubs Group Ag holds 68,440 shares of GLYC stock, worth $17,110. This represents 0.0% of its overall portfolio holdings.

Number of Shares

68,440

Previous 83,020 17.56%

Holding current value

$17,110

Previous $23,000 52.17%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.16 - $0.32 $2,332 - $4,665	-14,580 Reduced 17.56%	68,440 $11,000
Q2 2024 Aug 13, 2024	BUY	$0.24 - $3.04 $19,564 - $247,820	81,520 Added 5434.67%	83,020 $23,000
Q1 2024 May 13, 2024	BUY	$2.55 - $3.49 $2,083 - $2,851	817 Added 119.62%	1,500 $4,000
Q4 2023 Feb 09, 2024	BUY	$1.13 - $2.54 $771 - $1,734	683 New	683 $1,000
Q2 2023 Aug 11, 2023	SELL	$1.21 - $2.08 $6,167 - $10,601	-5,097 Reduced 44.63%	6,323 $11,000
Q1 2023 May 12, 2023	BUY	$1.25 - $4.05 $14,275 - $46,251	11,420 New	11,420 $14,000
Q3 2022 Nov 10, 2022	BUY	$0.55 - $0.9 $9,494 - $15,535	17,262 New	17,262 $10,000
Q2 2022 Aug 10, 2022	SELL	$0.54 - $1.15 $17 - $36	-32 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.0 - $1.58 $21,022 - $33,214	-21,022 Reduced 99.85%	32 $0
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.14 $30,271 - $44,987	21,022 Added 65693.75%	21,054 $30,000
Q3 2021 Nov 15, 2021	SELL	$1.8 - $2.39 $18,486 - $24,545	-10,270 Reduced 99.69%	32 $0
Q2 2021 Aug 13, 2021	SELL	$2.16 - $3.18 $37,048 - $54,543	-17,152 Reduced 62.48%	10,302 $24,000
Q1 2021 May 12, 2021	SELL	$2.89 - $4.22 $91,162 - $133,115	-31,544 Reduced 53.47%	27,454 $83,000
Q4 2020 Feb 11, 2021	BUY	$2.69 - $4.24 $43,354 - $68,336	16,117 Added 37.59%	58,998 $222,000
Q3 2020 Nov 12, 2020	SELL	$3.07 - $5.0 $34,884 - $56,815	-11,363 Reduced 20.95%	42,881 $132,000
Q2 2020 Jul 31, 2020	SELL	$2.06 - $3.76 $24,338 - $44,424	-11,815 Reduced 17.89%	54,244 $204,000
Q1 2020 May 01, 2020	SELL	$1.83 - $5.41 $41,899 - $123,867	-22,896 Reduced 25.74%	66,059 $151,000
Q4 2019 Feb 14, 2020	BUY	$4.03 - $6.5 $185,847 - $299,754	46,116 Added 107.65%	88,955 $471,000
Q3 2019 Nov 14, 2019	SELL	$2.8 - $12.85 $34,196 - $156,937	-12,213 Reduced 22.18%	42,839 $185,000
Q2 2019 Aug 14, 2019	SELL	$10.6 - $13.12 $200,562 - $248,243	-18,921 Reduced 25.58%	55,052 $656,000
Q1 2019 May 14, 2019	BUY	$9.96 - $13.44 $280,204 - $378,107	28,133 Added 61.37%	73,973 $922,000
Q4 2018 Feb 14, 2019	BUY	$8.47 - $14.71 $233,424 - $405,392	27,559 Added 150.75%	45,840 $434,000
Q3 2018 Nov 14, 2018	BUY	$13.7 - $17.12 $246,339 - $307,834	17,981 Added 5993.67%	18,281 $263,000
Q2 2018 Aug 14, 2018	SELL	$14.63 - $19.19 $1.83 Million - $2.4 Million	-125,055 Reduced 99.76%	300 $5,000
Q1 2018 May 15, 2018	BUY	$16.06 - $25.35 $2.01 Million - $3.17 Million	125,055 Added 41685.0%	125,355 $2.04 Million
Q4 2017 Feb 14, 2018	SELL	$10.51 - $17.22 $20,820 - $34,112	-1,981 Reduced 86.85%	300 $5,000
Q3 2017 Nov 14, 2017	BUY	$10.14 - $14.85 $18,779 - $27,502	1,852 Added 431.7%	2,281 $32,000
Q2 2017 Aug 14, 2017	SELL	N/A	-1,380 Reduced 76.29%	429 $4,000
Q1 2017 Nov 14, 2017	BUY	N/A	1,809	1,809 $10,000

Others Institutions Holding GLYC

# of Institutions

Shares Held

17.8M

Call Options Held

Put Options Held

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $13.1M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account